Thymosin-α1 in Cancer-Related Fatigue
Primary Purpose
Cancer Related Fatigue, Quality of Life
Status
Unknown status
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Thymosin-α1
Sponsored by
About this trial
This is an interventional treatment trial for Cancer Related Fatigue
Eligibility Criteria
Inclusion Criteria:
- Men and women aged 18 years and older.
- The life expectancy at least 6 months.
- With a definite pathological diagnosis of cancer, and undergo chemotherapy.
- Patients who are willing to participate in the study.
Exclusion Criteria:
- Thymosin-α1 allergy.
- Using the spirit excitement or stimulant drugs.
- With brain metastasis or primary malignant brain tumors.
- With mental disorders, such as suffering from dementia, delirium, obsessive-compulsive disorder, schizophrenia, epilepsy.
- Other specific causes of fatigue: such as anemia, thyroid function is low, insomnia, uncontrolled pain.
- Serious HRS cardiopulmonary function disorder.
- Women during pregnancy and lactation.
Sites / Locations
- Cancer instituteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Arm T
Arm B
Arm Description
Will be treated with Thymosin-α1 1.6mg twice a week from day 1 of chemotherapy
With best support according to NCCN Guideline
Outcomes
Primary Outcome Measures
Change in Cancer-Related Fatigue Scale
Secondary Outcome Measures
improvement in Quality of Life
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02127268
Brief Title
Thymosin-α1 in Cancer-Related Fatigue
Official Title
Thymosin-α1 for Cancer-Related Fatigue in Cancer Patients Who Undergo Chemotherapy: A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Unknown status
Study Start Date
April 2014 (Actual)
Primary Completion Date
April 2020 (Anticipated)
Study Completion Date
December 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Zhigang Zhang
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Cancer-related fatigue (CRF) is a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportion to recent activity and interferes with usual functioning. Compared with general fatigue, CRF have the characteristics of long duration and generally cannot alleviate by rest or sleep, serious impact on the patient's work, study, entertainment and family life, and thus greatly affect the recovery, self-care ability and life quality of patients. Many dates showed that 70%~100% of cancer patients experienced cancer-related fatigue.For cancer-related fatigue there is no good treatment and intervention, in recent years, many clinical trials are carried out; central nervous stimulant, such as methylphenidate; acupuncture, aerobic exercise. All those measures may have certain therapeutic effect for CRF, but don't have exact evidences from massive RCT to confirm.
Thymosin-α1 (T-α1), a synthetic 28-amino acid peptide with multiple biological activities primarily directed towards immune response enhancement, this drug is used for the treatment of HBV and hepatitis C virus (HCV) infections, and being developed for the treatment of non-small cell lung cancer (NSCLC), hepatocellular carcinoma, AIDS and malignant melanoma. T-α1 is able to potentiate the action of cytokines and also reduce the hematological toxicity of cytotoxic drug therapy, such as cyclophosphamide, 5-fluorouracil, dacarbazine.
In this studies, we want to demonstrated that the effectiveness of Thymosin-α1 for cancer-related fatigue in cancer patients who undergo chemotherapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer Related Fatigue, Quality of Life
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Arm T
Arm Type
Active Comparator
Arm Description
Will be treated with Thymosin-α1 1.6mg twice a week from day 1 of chemotherapy
Arm Title
Arm B
Arm Type
No Intervention
Arm Description
With best support according to NCCN Guideline
Intervention Type
Drug
Intervention Name(s)
Thymosin-α1
Intervention Description
with Thymosin-α1 1.6mg twice a week
Primary Outcome Measure Information:
Title
Change in Cancer-Related Fatigue Scale
Time Frame
baseline and 4 weeks
Secondary Outcome Measure Information:
Title
improvement in Quality of Life
Time Frame
baseline and 4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women aged 18 years and older.
The life expectancy at least 6 months.
With a definite pathological diagnosis of cancer, and undergo chemotherapy.
Patients who are willing to participate in the study.
Exclusion Criteria:
Thymosin-α1 allergy.
Using the spirit excitement or stimulant drugs.
With brain metastasis or primary malignant brain tumors.
With mental disorders, such as suffering from dementia, delirium, obsessive-compulsive disorder, schizophrenia, epilepsy.
Other specific causes of fatigue: such as anemia, thyroid function is low, insomnia, uncontrolled pain.
Serious HRS cardiopulmonary function disorder.
Women during pregnancy and lactation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhigang Zhang
Phone
8657187315009
Email
zzg2011@zju.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jian Huang, Doctor
Organizational Affiliation
Zhejiang University
Official's Role
Study Director
Facility Information:
Facility Name
Cancer institute
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310009
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhigang Zhang
Phone
8657187315009
Email
zzg2011@zju.edu.cn
12. IPD Sharing Statement
Learn more about this trial
Thymosin-α1 in Cancer-Related Fatigue
We'll reach out to this number within 24 hrs